Crohn’s disease Archives - Drugs in Context

Nurses’ perceptions on the usability of the Hyrimoz® Sensoready® autoinjector device

Charlotte Both, Elena Bachinskaya, Laura Rose, Carol M Antequera, Jessica R Allegretti

Article Type

Original Research

Published

17 Sep 2025

This survey of gastroenterology nurses in the USA was designed to assess nurses’ perceptions regarding the Hyrimoz Sensoready pen, and the degree to which unique features might influence patient education when compared with the reference medicine autoinjector device, the Humira pen.

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease – where we are and where we are going

Eleanor Liu, Nasar Aslam, Gaurav Nigam, Jimmy K Limdi

Article Type

Review

Published

11 Apr 2022

This narrative review summarizes the current literature regarding the mechanism of action of tofacitinib, data from registrational trials, emerging real-world evidence, and an overview of the most recent safety evidence. The authors explore evolving treatment paradigms and also present a brief overview of the next generation of JAK inhibitors in the pipeline.

Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors

Keira A Fieldhouse Bsc, Samantha Ukaibe BSc, Erika L Crowley BSc, MSc, Reena Khanna MD, MSc, FRCPC, Ashley O’Toole MD, MHSc, FRCPC, Melinda J Gooderham MD, MSc, FRCPC

Article Type

Review

Published

21 Apr 2020

This paper reviews all incident cases and exacerbations of IBD reported in the literature during widescale use of IL-17 inhibitors beyond the clinical trials.

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms

Benjamin Crooks MA MBBS, Tom Barnes MBBS BSc, Jimmy K Limdi FRCP FACG

Article Type

Review

Published

02 Mar 2020

This review brings together data reported on VDZ to date for treatment of inflammatory bowel diseases, comprising Crohn’s disease (CD) and ulcerative colitis (UC).